Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
News|Articles|March 13, 2024
Top 5 CROI 2024 Stories
Author(s)Contagion Editorial Team
This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.
Advertisement
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
Advertisement
Advertisement